Int J Oral Maxillofac Implants. 2019 July/August;34(4):e51–e63. doi: 10.11607/jomi.7236. Epub 2019 Feb 4.
Achieving successful and predictable alveolar ridge augmentation in the vertical dimension is extremely challenging. Several materials have been investigated to achieve vertical ridge augmentation; however, the results are highly unpredictable. The collaborative team presenting this research has developed brushite- and monetite-based grafts that incorporate in their matrix a novel bone anabolic conjugate (C3) of a bisphosphonate and a potent bone-activating EP4 receptor agonist. The study objective was to investigate the potential of these graft formulations to achieve rapid, enhanced, and clinically significant bone regeneration in the vertical dimension.
Brushite and monetite grafts were fabricated and characterized for phase purity, porosity, compressive strength, and microstructural morphology. They were implanted in 12 rabbit calvaria for 12 weeks. Each group (n = 6): brushite control, brushite with C3, monetite control, and monetite with C3. Postmortem samples were retrieved and processed for analysis. The percentage bone volume, vertical bone height gained, and graft resorption were calculated and assessed.
The brushite and monetite grafts containing C3 integrated well onto the calvarial bone surface, with new bone extending through the graft area (36% and 80%, respectively), while the C3 lacking grafts showed decreased surface integration and bone infiltration (28% and 38%, respectively). The C3 containing brushite and monetite grafts demonstrated bone growth vertically (1.8 mm and 2.7 mm, respectively) and improved graft resorption.
The brushite- and monetite-based grafts loaded with the C3 conjugate resulted in greater de novo bone formation in the vertical dimension when compared with the grafts without the drug. However, the monetite grafts produced much more and predictable vertical height gain than was achieved with brushite grafts. The advantages of this new graft drug formulation in future would be to provide more predictable vertical bone regeneration, which will ultimately benefit patients undergoing dental implant placement.
在垂直方向上成功且可预测地实现牙槽嵴增大极具挑战性。已经研究了几种材料来实现垂直嵴增大，但结果高度不可预测。提交本研究的协作团队开发了基于磷酸钙水合物和磷酸钙的移植物，其基质中包含一种新型双膦酸盐和一种有效的骨激活 EP4 受体激动剂的骨合成代谢偶联物 (C3)。研究目的是研究这些移植物配方在垂直方向上实现快速、增强和临床显著骨再生的潜力。
制备并表征磷酸钙水合物和磷酸钙的移植物的相纯度、孔隙率、抗压强度和微观结构形态。它们被植入 12 只兔颅骨 12 周。每组（n = 6）：磷酸钙水合物对照、含 C3 的磷酸钙水合物、磷酸钙对照和含 C3 的磷酸钙。取出并处理死后样本进行分析。计算并评估骨体积百分比、获得的垂直骨高度和移植物吸收。
含 C3 的磷酸钙水合物和磷酸钙移植物与颅骨骨表面很好地整合在一起，新骨穿过移植物区域（分别为 36%和 80%），而不含 C3 的移植物显示出表面整合和骨渗透减少（分别为 28%和 38%）。含 C3 的磷酸钙水合物和磷酸钙移植物在垂直方向上表现出骨生长（分别为 1.8 毫米和 2.7 毫米）和改善的移植物吸收。
与不含药物的移植物相比，负载 C3 偶联物的磷酸钙水合物和磷酸钙基移植物在垂直方向上导致更多的新骨形成。然而，磷酸钙移植物产生的垂直高度增益比磷酸钙水合物移植物更可预测。这种新的移植物药物制剂的优势将是提供更可预测的垂直骨再生，这将最终使接受牙种植体放置的患者受益。
